Syndax Pharmaceuticals Inc

NASDAQ:SNDXUnited States

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Contact Information

Headquarters

35 Gatehouse Drive, Building D, Floor 3WALTHAM, MA, United States 02451

Phone

781-419-1400

Fax

781-419-1420

Executives

Independent Chairman of the Board

Dennis Podlesak

President, Head of Research and Development

Neil Gallagher

Chief Executive Officer, Director

Michael Metzger

Chief Financial Officer, Principal Accounting Officer, Treasurer

Keith Goldan

Chief Scientific Officer

Peter Ordentlich